

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPplus enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

DICTIONARY FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



```

chain nodes :
18 19 32 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29
30
chain bonds :
11-18 18-19 29-32 30-33 33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :
```

G1:C,O

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:28:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 685 TO ITERATE

100.0% PROCESSED 685 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 12130 TO 15270

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:28:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14347 TO ITERATE

100.0% PROCESSED 14347 ITERATIONS

42 ANSWERS

SEARCH TIME: 00.00.01

L3 42 SEA SSS FUL L1

=> s l3 and caplus/lc

69514057 CAPLUS/LC


L4 37 L3 AND CAPLUS/LC

=> s l3 not l4

L5 5 L3 NOT L4

=> d l5 1-5


L5 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1027502-87-9 REGISTRY
 ED Entered STN: 12 Jun 2008
 CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)
 MF C29 H28 F2 N4 O
 SR Other Sources
 Database: ChemSpider (ChemZoo, Inc.)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1027155-70-9 REGISTRY
 ED Entered STN: 11 Jun 2008
 CN 2H-Benzimidazol-2-one, 6-[(Z)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H25 F2 N3 O3
 SR Other Sources
 Database: ChemSpider (ChemZoo, Inc.)


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1027048-35-6 REGISTRY
 ED Entered STN: 10 Jun 2008
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H26 F2 N4 O2
 SR Other Sources
 Database: ChemSpider (ChemZoo, Inc.)


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1026946-78-0 REGISTRY
 ED Entered STN: 10 Jun 2008
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro-, rel- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H29 F2 N3 O3
 SR Other Sources
 Database: ChemSpider (ChemZoo, Inc.)


Relative stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026047-11-9 REGISTRY
ED Entered STN: 06 Jun 2008
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-
ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(1-piperazinyl)ethyl]-
(CA INDEX NAME)
FS STEREOSEARCH
MF C29 H28 F2 N4 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          201.96      202.18
```

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Dec 2009 VOL 151 ISS 26
 FILE LAST UPDATED: 17 Dec 2009 (20091217/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

```
L1      STRUCTURE UPLOADED
L2      1 S L1
L3      42 S L1 FULL
L4      37 S L3 AND CAPLUS/LC
L5      5 S L3 NOT L4
```

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

=> s l4

```
L6      2 L4
```

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):n

=> d ibib abs hitstr 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 2005:638871 CAPLUS
DOCUMENT NUMBER: 143:153374
TITLE: Preparation of tricyclic steroid hormone nuclear receptor modulators
INVENTOR(S): Gavardinas, Konstantinos; Green, Jonathan Edward; Jadhav, Prabhakar Kondaji; Matthews, Donald P.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXX22
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066161	A1	20050721	WO 2004-US38233	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GE, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312293	A1	20050721	AU 2004-312293	20041208
CA 2549053	A1	20050721	CA 2004-2549053	20041208
EP 1697350	A1	20060906	EP 2004-811084	20041208
EP 1697350	B1	20080625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1918151	A	20070221	CN 2004-80041853	20041208
BR 2004016882	A	20070227	BR 2004-16882	20041208
JP 2007515431	T	20070614	JP 2006-545655	20041208
AT 399163	T	20080715	AT 2004-811084	20041208
ES 2308296	T3	20081201	ES 2004-811084	20041208
US 20070037788	A1	20070215	US 2006-576761	20060421
ZA 2006004889	A	20071128	ZA 2006-4889	20060613
MX 2006007055	A	20070130	MX 2006-7055	20060619
IN 2006DN03757	A	20070622	IN 2006-DN3757	20060629
NO 2006003329	A	20060914	NO 2006-3329	20060718
PRIORITY APPLN. INFO.:			US 2003-531283P	P 20031219
			WO 2004-US38233	W 20041208

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:153374; MARPAT 143:153374
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [Y = CH₂, O; R1-2 = H, F; R3 = Z-amino, Z-heterocyclyl; Z = divalent alkyl; with some specific exceptions] are prepared For instance,

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RN 860009-99-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-00-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
II is prepd. from (E)-11-bromomethylene-3-fluoro-6,11-dihydrodibenz[b,e]oxepine (prepn. given) and 1-(1,1-dimethyl-2-(morpholin-4-yl)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-dihydrobenzimidazol-2-one (prepn. given) (dioxane, Na₂CO₃, [Ph₃P]₄Pd, 90-100°, 5 days). II has K_i ≤ 500 nM for the mineralocorticoid receptor and K_i ≤ 1,000 nM for the glucocorticoid receptor. I are useful for the treatment of congestive heart disease, hypertension, rheumatoid arthritis or inflammation.


IT 710344-06-2P 860009-94-5P 860009-99-0P
860010-00-0P 860010-01-1P 860010-03-3P
860010-04-4P 860010-06-6P 860010-07-7P
860010-12-4P 860010-13-5P 860010-14-6P
860010-15-7P 860010-16-8P 860010-17-9P
860010-19-1P 860010-21-5P 860010-30-6P
860010-32-8P 860010-38-4P 860010-40-8P
860010-42-0P 860010-44-2P 860010-45-3P
860010-46-4P 860010-54-4P 860010-55-5P
860010-56-6P 860010-57-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolone-substituted tricyclic steroid hormone nuclear receptor modulators)

RN 710344-06-2 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 860009-94-5 CAPLUS


CN 2H-Benzimidazol-2-one, 1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)


RN 860010-01-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 860010-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 860010-06-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 860010-07-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-12-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-13-5 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-14-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 860010-15-7 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 860010-16-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-17-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1,1-dimethylethyl]-1,3-dihydro-, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 860010-19-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-21-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 860010-30-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 860010-32-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 860010-38-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-40-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 860010-42-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1,1-dimethyl-2-(4-morpholinyl)ethyl)-1,3-dihydro-, rel- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-44-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2R,6S)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 860010-45-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 860010-46-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 860010-57-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT



RN 860010-54-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)



RN 860010-55-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 860010-56-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(dimethylamino)ethyl]- (CA INDEX NAME)

ACCESSION NUMBER: 2004:515475 CAPLUS
DOCUMENT NUMBER: 141:71360
TITLE: Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions
INVENTOR(S): as steroid hormone nuclear receptor modulators
Coghlan, Michael Joseph; Green, Jonathan Edward; Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Steinberg, Mitchell Irvin; Fales, Kevin Robert; Bell, Michael Gregory
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 457 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052847	A2	20040624	WO 2003-US16213	20030613
WO 2004052847	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489276	A1	20040624	CA 2003-2489276	20030613
AU 2003302220	A1	20040630	AU 2003-302220	20030613
AU 2003302220	B2	20090326		
BR 2003012095	A	20050329	BR 2003-12095	20030613
EP 1519915	A2	20050406	EP 2003-810038	20030613
EP 1519915	B1	20090527		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665780	A	20050907	CN 2003-815098	20030613
CN 1331848	C	20070815		
JP 2005539088	T	20051222	JP 2004-559025	20030613
CN 101161641	A	20080416	CN 2007-10112172	20030613
AT 432257	T	20090615	AT 2003-810038	20030613
ES 2325861	T3	20090922	ES 2003-810038	20030613
US 20060063759	A1	20060323	US 2004-517010	20041203
US 7411072	B2	20080812		
IN 2004KN01910	A	20070126	IN 2004-KN1910	20041213
MX 2004012998	A	20050516	MX 2004-12998	20041217
ZA 2004010293	A	20060222	ZA 2004-10293	20041221
NO 2005000397	A	20050304	NO 2005-397	20050125
US 20090149445	A1	20090611	US 2008-173059	20080715
PRIORITY APPLN. INFO.:				
			CN 2003-815098	A3 20030613
			WO 2003-US16213	W 20030613

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:71360
GI




AB Dibenzosuberone derivs., such as I [X = CH₂; R, R₁ = H, OH, CN, halogen, alkoxy, sulfonylamino, amino, etc.; R₂ = aryl, heteroaryl; R₃ = H, alkyl], and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of pathol. disorders susceptible to steroid hormone nuclear receptor modulation. These compds.


are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer,

peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varices, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease,. Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance,


chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyarteritis nodosa, Wegener's



RN 710345-76-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710345-77-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710345-83-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis,. Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus,, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multiple sclerosis. Thus, dibenzosuberone deriv. II (R = NHMe) was prepd. with


48% yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with

MeNH₂ in THF. The prepd. dibenzosuberone derivs. and analogs were assayed for mineralocorticoid and glucocorticoid receptor binding.


IT 710344-04-OP 710344-06-2P 710345-76-9P
710345-77-OP 710345-83-8P 710345-85-OP
710346-10-4P 710346-11-5P 710346-12-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of derivs. and heterocyclic analogs of dibenzosuberone for use in pharmaceutical compns. as steroid hormone nuclear receptor modulators)


RN 710344-04-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 710344-06-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 710345-85-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 710346-10-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 710346-11-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 710346-12-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
 RECORD (14 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
14.28	216.46

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.64	-1.64

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2
DICTIONARY FILE UPDATES: 16 DEC 2009 HIGHEST RN 1197964-91-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30

exact/norm bonds :

5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

G1:C,0

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 13:33:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 685 TO ITERATE

100.0% PROCESSED 685 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 12130 TO 15270

PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> s 17 full

FULL SEARCH INITIATED 13:33:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14347 TO ITERATE

100.0% PROCESSED 14347 ITERATIONS


0 ANSWERS

SEARCH TIME: 00.00.03

L9 0 SEA SSS FUL L7

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30

exact/norm bonds :

5-7 6-11 7-8 8-9 10-11 11-18 18-19 22-23 22-27 22-28 23-24 23-30 24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15
isolated ring systems :
containing 1 :

G1:C,O

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

L10 STRUCTURE UPLOADED

=> d

L10 HAS NO ANSWERS

L10 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 119

L19 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 110

SAMPLE SEARCH INITIATED 13:35:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4987 TO ITERATE

40.1% PROCESSED 2000 ITERATIONS 0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 95505 TO 103975

PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s 119 full

L19 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 110 full

FULL SEARCH INITIATED 13:35:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 100911 TO ITERATE



100.0% PROCESSED 100911 ITERATIONS
SEARCH TIME: 00.00.05

0 ANSWERS

L12 0 SEA SSS FUL L10

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10576761.str



chain nodes :

18 19 32 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 22 23 24 25 26 27 28 29
30

chain bonds :

11-18 18-19 29-32 30-33 33-34

```

ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-11  7-8  8-9  9-10  9-12  10-11  10-15  12-13
13-14 14-15 22-23 22-27 22-28 23-24 23-30 24-25 25-26 26-27 28-29 29-30
exact/norm bonds :
5-7  6-11  7-8  8-9  10-11  11-18  18-19  22-23  22-27  22-28  23-24  23-30  24-25
25-26 26-27 28-29 29-30 29-32 30-33 33-34
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-12  10-15  12-13  13-14  14-15
isolated ring systems :
containing 1 :

```

G1:C,O

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS

```

L13 STRUCTURE UPLOADED

```

=> d
L13 HAS NO ANSWERS
L13 STR

```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```

=> s l13
SAMPLE SEARCH INITIATED 13:36:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4987 TO ITERATE

```

```

40.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 95505 TO 103975
PROJECTED ANSWERS: 1 TO 143

```

L14 1 SEA SSS SAM L13

```

=> s l13 full
FULL SEARCH INITIATED 13:36:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 100911 TO ITERATE

```

```

100.0% PROCESSED 100911 ITERATIONS 83 ANSWERS
SEARCH TIME: 00.00.05

```

L15 83 SEA SSS FUL L13

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 42 S L1 FULL
L4 37 S L3 AND CAPLUS/LC
L5 5 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

L6 2 S L4

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009

L7 STRUCTURE UPLOADED
L8 0 S L7
L9 0 S L7 FULL
L10 STRUCTURE UPLOADED
L11 0 S L10
L12 0 S L10 FULL
L13 STRUCTURE UPLOADED
L14 1 S L13
L15 83 S L13 FULL

=> s l15 not l3

L16 43 L15 NOT L3

=> s l16 and caplus/lc

69529862 CAPLUS/LC

L17 31 L16 AND CAPLUS/LC


=> s l16 not l17

L18 12 L16 NOT L17

=> d l18 12

L18 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860010-47-5 REGISTRY
ED Entered STN: 12 Aug 2005
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-
ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX
NAME)
FS STEREOSEARCH
MF C28 H25 F2 N3 O2
CI CCM
SR CA

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	567.92	784.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-1.64

FILE 'CAPLUS' ENTERED AT 13:37:20 ON 18 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Dec 2009 VOL 151 ISS 26
FILE LAST UPDATED: 17 Dec 2009 (20091217/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:27:14 ON 18 DEC 2009)

FILE 'REGISTRY' ENTERED AT 13:27:32 ON 18 DEC 2009

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 42 S L1 FULL
L4 37 S L3 AND CAPLUS/LC
L5 5 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:28:40 ON 18 DEC 2009

L6 2 S L4

FILE 'REGISTRY' ENTERED AT 13:32:04 ON 18 DEC 2009

L7 STRUCTURE UPLOADED
L8 0 S L7


```
L9          0 S L7 FULL
L10         STRUCTURE UPLOADED
L11         0 S L10
L12         0 S L10 FULL
L13         STRUCTURE UPLOADED
L14         1 S L13
L15        83 S L13 FULL
L16        43 S L15 NOT L3
L17        31 S L16 AND CAPLUS/LC
L18        12 S L16 NOT L17
```

FILE 'CAPLUS' ENTERED AT 13:37:20 ON 18 DEC 2009

=> s 117

```
L19          1 L17
```

=> d 119

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:638871 CAPLUS
 DN 143:153374
 TI Preparation of tricyclic steroid hormone nuclear receptor modulators
 IN Gavardinas, Konstantinos; Green, Jonathan Edward; Jadhav, Prabhakar
 Kondaji; Matthews, Donald P.
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005066161	A1	20050721	WO 2004-US38233	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312293	A1	20050721	AU 2004-312293	20041208
CA 2549053	A1	20050721	CA 2004-2549053	20041208
EP 1697350	A1	20060906	EP 2004-811084	20041208
EP 1697350	B1	20080625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1918151	A	20070221	CN 2004-80041853	20041208
BR 2004016882	A	20070227	BR 2004-16882	20041208
JP 2007515431	T	20070614	JP 2006-545655	20041208
AT 399163	T	20080715	AT 2004-811084	20041208
ES 2308296	T3	20081201	ES 2004-811084	20041208
US 20070037788	A1	20070215	US 2006-576761	20060421
ZA 2006004889	A	20071128	ZA 2006-4889	20060613
MX 2006007055	A	20070130	MX 2006-7055	20060619
IN 2006DN03757	A	20070622	IN 2006-DN3757	20060629
NO 2006003329	A	20060914	NO 2006-3329	20060718
PRAI US 2003-531283P	P	20031219		
WO 2004-US38233	W	20041208		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS CASREACT 143:153374; MARPAT 143:153374
 OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.75

786.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.64

STN INTERNATIONAL LOGOFF AT 13:37:40 ON 18 DEC 2009